Clinical Trial

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Study acronym: GBGT
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-17
Trial Details
NCT Number NCT07313813
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 20 participants
Start Date 2025-12-29
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-16